| Bioactivity | HIV-1 inhibitor-13 (compound 16c) is a orally active and potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI), with IC50 of 0.14 μM (HIV-1 RT). HIV-1 inhibitor-13 shows activity against a panel of HIV-1 resistant strains, with EC50 values of 2.85-18.0 nM[1]. |
| In Vivo | HIV-1 inhibitor-13 (compound 16c) (SD rats; 2 mg/kg, IV; 10 mg/kg, PO; once) exhibits favorable pharmacokinetic profiles (F = 32.1% and T1/2 = 0.88 and 1.05 h, respectively)[1].HIV-1 inhibitor-13 (Kunming mice, 2000 mg/kg, PO, once) shows safety in Kunming mice (LD50 > 2000 mg/kg)[1]. |
| Name | HIV-1 inhibitor-13 |
| Formula | C30H32N6O3 |
| Molar Mass | 524.61 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kang D, et al. Development of Novel Dihydrofuro[3,4-d]pyrimidine Derivatives as HIV-1 NNRTIs to Overcome the Highly Resistant Mutant Strains F227L/V106A and K103N/Y181C. J Med Chem. 2022 Feb 10;65(3):2458-2470. |